MedDataX Logo

Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line

NCT ID: NCT03288298

Last Updated: 2017-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-01

Study Completion Date

2019-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than luteolin on tongue squamous cell carcinoma cell line.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is conducted to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than luteolin on tongue squamous cell carcinoma cell line. The primary outcome is apoptosis, while the secondary outcome is cell viability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tongue Neoplasms Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

luteolin

a natural extract derived flavinoids

Group Type EXPERIMENTAL

luteolin

Intervention Type DRUG

flavonoid natural extract

nano-luteolin

nano-particles derived from a natural extract luteolin

Group Type ACTIVE_COMPARATOR

nano-luteolin

Intervention Type DRUG

nanoparticles of luteolin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

luteolin

flavonoid natural extract

Intervention Type DRUG

nano-luteolin

nanoparticles of luteolin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

3',4',5,7-tetrahydroxyflavone nanoluteolin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Squamous cell carcinoma cell lines (OSCC, TSCC and HNSCC).
* Luteolin 5,7,3',4'-tetrahydroxy-flavone (MeSH term).
* Application of luteolin as a chemotherapeutic drug.

Exclusion Criteria

* Any cancer cell line other than OSCC, TSCC and HNSCC cell lines.
* Luteolin glycosides.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Safaa Elbaz

Assistant Lecturer, Oral and Maxillofacial Pathology, BUE

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed Elkhadem, PhD

Role: STUDY_CHAIR

Center for Evidence Based Dentistry

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Safaa M. Baz, Masters

Role: CONTACT

[email protected]
002 01119777824

Safa F. Abd El-Ghani, PhD

Role: CONTACT

[email protected]
002 01005198010

References

Explore related publications, articles, or registry entries linked to this study.

Ding S, Hu A, Hu Y, Ma J, Weng P, Dai J. Anti-hepatoma cells function of luteolin through inducing apoptosis and cell cycle arrest. Tumour Biol. 2014 Apr;35(4):3053-60. doi: 10.1007/s13277-013-1396-5. Epub 2013 Nov 28.

Reference Type BACKGROUND
PMID: 24287949 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEBD-CU-2017-09-23

Identifier Type: -

Identifier Source: org_study_id